Tianjin dev (00882) announced that tianjin lisheng pharmaceutical, an indirectly wholly-owned subsidiary, achieved total operating income of 1.024 billion yuan (RMB, the same below) for the nine months ended September 30, 2024, a year-on-year increase of 12.3%; net income attributable to the owners of the parent company was 0.169 billion yuan, a year-on-year decrease of 50.6%; and basic earnings per share was 0.66 yuan.
天津发展：力生制药前三季度归母净利润1.69亿元 同比下降50.6%
Tianjin dev: Tianjin Lisheng Pharmaceutical's net income attributable to the parent company in the first three quarters decreased by 50.6% to 0.169 billion yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha
【November 2024】Has disney's predicament turned around? Pay attention to these 3 performance signals.
As the entertainment kingdom for nearly a century, Disney's status in Hollywood has gained prominence. Over 60 years of listing on the U.S. stock market, Disney